Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 799 across all filing types
Latest filing 2019-04-09 Capital/Financing Update
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming Group announces completion of minority investment in BioConnection BV
Capital/Financing Update Classification · 98% confidence The document is a press release from Pharming Group N.V. announcing the completion of a minority investment in its partner, BioConnection BV. It details the financial transaction (€4.1 million total investment via cash and credit conversion) and the strategic rationale (securing increased Fill & Finish capacity for RUCONEST®). This type of announcement, detailing fundraising, capital structure changes, or significant strategic investments/acquisitions (even minority stakes), falls under the Capital/Financing Update category. It is not a full annual report (10-K), an earnings release (ER), or a management discussion (MDA), but rather a specific corporate action related to capital structure and financing activities.
2019-04-09 English
Pharming Group announces publication of its Annual Report 2018 and a provisional commitment to invest in supplier
Report Publication Announcement Classification · 100% confidence The document is explicitly titled "Pharming Group announces publication of its Annual Report 2018". It contains key highlights and details about where the full Annual Report 2018 can be downloaded. Although it announces the publication of the Annual Report (which might suggest RPA), the document itself is a press release detailing significant corporate news (the report publication AND a provisional investment commitment in a supplier). Given the explicit mention of the 'Annual Report 2018' and the context of a major yearly filing, the primary subject is the Annual Report. However, the document structure strongly resembles a press release announcing the availability of the formal filing, rather than the filing itself (which would typically be a 10-K or AR). Since the document's main purpose is to announce the publication of the Annual Report and provide a link, it fits the definition of a Report Publication Announcement (RPA) better than the comprehensive 10-K or AR, which are usually much longer and contain the full audited statements directly. The document length (7112 chars) is substantial but still functions as an announcement wrapper for the main report.
2019-03-29 English
Annual Report 2018
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2018' and contains comprehensive sections including the CEO's statement, operational and financial highlights, management report, corporate governance, and full consolidated financial statements (income statement, balance sheet, cash flows, etc.). It covers the full fiscal year 2018 and adheres to the definition of an Annual Report (10-K equivalent for international entities). FY 2018
2019-03-28 English
Pharming Group Reports Strong Preliminary Financial Results for 2018 including first year of net profit
Earnings Release Classification · 100% confidence The document text explicitly states: 'Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) presents its preliminary (unaudited) financial report for the full year ended 31 December 2018.' It contains detailed financial summaries, income statements, balance sheets, and management commentary on the year's performance, including revenue, net profit, and operating profit. This content aligns perfectly with the definition of a comprehensive annual financial report, which corresponds to the 10-K filing type, even though the document itself might be an 'Earnings Release' or 'Interim Report' in structure, the scope (full year results) points to the annual filing category. Since it is a comprehensive report covering the full fiscal year, 10-K is the most appropriate classification among the provided options, despite the 'preliminary' nature, as it serves the function of the annual review. FY 2018
2019-03-07 English
Pharming announces abstract presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and sponsorship of the AAAAI Foundation Michael M. Frank, MD, FAAAI Lectureship
Regulatory Filings
2019-02-25 English
Pharming announces abstracts presented at The Western Society of Allergy, Asthma & Immunology (WSAAI) conference this week
Regulatory Filings
2019-01-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.